Research programme: ROR gamma receptor modulators - Escalier Biosciences

Drug Profile

Research programme: ROR gamma receptor modulators - Escalier Biosciences

Alternative Names: Research programme: ROR modulators - Escalier Biosciences; Research programme: RORγt modulators - Escalier Biosciences; ROR-gamma modulators - Escalier Biosciences; RORγ modulators - Escalier

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Escalier Biosciences
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Psoriasis

Most Recent Events

  • 13 Aug 2018 Escalier Biosciences plans a clinical trial for psoriasis in the first half of 2019 (PO)
  • 13 Mar 2018 Escalier Biosciences plans to initiate human proof-of-concept studies for Psoriasis in mid-2018 (Topical, PO)
  • 13 Mar 2018 Preclinical trials in Autoimmune disorders in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top